Breast Cancer Foundation NZ
Ronald Kay Science Fellowship for 2018
April 2018
What is the problem and who is affected?
Dr Barbara Lipert, a research fellow at the University of Auckland, is investigating resistance to Kadcyla, a relatively new drug for advanced HER2+ breast cancer that has been recommended for funding by PHARMAC, but with a low priority ranking until further investigations are completed.
What is this research hoping to achieve?
Dr Lipert plans to build on work at Auckland University that has already identified several genes that could be factors in resistance to Kadcyla. “We need to evaluate these findings in a multistage process now. This knowledge will help clinicians and patients make informed decisions in choosing the best treatment strategy, bringing us closer to making personalised medicine a reality in breast cancer treatment in New Zealand.”
-
SeptemberResearch Grant
Tackling side-effects of chemotherapy
-
SeptemberResearch Grant
Virus-based vaccine for TNBC
-
AugustResearch Grant
Improving equality in breast cancer care
-
AugustResearch Grant
Analysis of DCIS data in the Breast Cancer Foundation National Register
-
AugustResearch Grant
Gaps in the provision of radiotherapy for early breast cancer
-
AugustResearch Grant
Immunotherapy in breast cancer
-
JulyResearch Grant
A Vaccine for HER2+ advanced breast cancer
-
JulyResearch Grant
Finding a targeted drug for triple negative breast cancer
-
JuneResearch Grant
Using fat stem cells to improve breast reconstruction
-
JuneResearch Grant
Digital pathology for more accurate breast cancer diagnosis
-
April
Ronald Kay Science Fellowship for 2018
-
AprilBelinda Scott Fellowship
BCFNZ Belinda Scott Clinical Fellowship for 2018
-
MarchResearch Grant
Year 2: Five-year research partnership targets breast cancer vaccine